Erratum: Connecting genetic risk to disease end points through the human blood plasma proteome(Nature Communications (2017) 8 (14357) DOI: 10.1038/ncomms14357);Connecting genetic risk to disease end points through the human blood plasma proteome

Nature Communications

Volumn 8, Issue , 2017, Pages

  Suhre, Karsten ^a   Arnold, Matthias ^b   Bhagwat, Aditya Mukund ^a   Cotton, Richard J ^a   Engelke, Rudolf ^a   Raffler, Johannes ^b   Sarwath, Hina ^a   Thareja, Gaurav ^a   Wahl, Annika ^b   Delisle, Robert Kirk ^c   Gold, Larry ^c   Pezer, Marija ^d   Lauc, Gordan ^d   Selim, Mohammed A El Din ^e   Mook Kanamori, Dennis O ^f   Al Dous, Eman K ^a   Mohamoud, Yasmin A ^a   Malek, Joel ^a   Strauch, Konstantin ^b,g   Grallert, Harald ^b,h   Peters, Annette ^b,h,i   Kastenmüller, Gabi ^b,h   Gieger, Christian ^b,j   Graumann, Johannes ^a   more..

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c SomaLogic Inc   (United States)

^d GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

^e HAMAD MEDICAL CORPORATION   (Qatar)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF MUNICH   (Germany)

^h GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

ⁱ DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^j MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; PROTEOME; COMPLEMENT; GLYCOPROTEIN; HEME; MESSENGER RNA; PLASMA PROTEIN;

BLOOD; COHORT ANALYSIS; DISEASE PREVALENCE; DRUG; GENE; GENETIC VARIATION; GENOME; METABOLITE; PROTEIN; PROTEOMICS;

ADULT; AGED; ALZHEIMER DISEASE; ARAB; ARTICLE; ASIAN; AUTOIMMUNE DISEASE; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOME; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GERMAN (CITIZEN); HUMAN; PHARMACOGENETICS; PROTEIN PROCESSING; PROTEOMICS; QUANTITATIVE TRAIT LOCUS; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; ALLELE; BIOASSAY; DRUG DELIVERY SYSTEM; GENE REGULATORY NETWORK; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; HUMAN GENOME; METABOLISM; MOLECULAR GENETICS; REPRODUCIBILITY; RISK FACTOR;

ASIA; GERMANY;

ALLELES; BLOOD PROTEINS; COMPLEMENT SYSTEM PROTEINS; DRUG DELIVERY SYSTEMS; ENDPOINT DETERMINATION; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; GLYCOPROTEINS; HEME; HUMANS; MOLECULAR SEQUENCE ANNOTATION; PHARMACOGENETICS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; QUANTITATIVE TRAIT LOCI; REPRODUCIBILITY OF RESULTS; RISK FACTORS; RNA SPLICING; RNA, MESSENGER;

EID: 85014061753     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15345     Document Type: Erratum

References (72)

1. Suhre, K. et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477, 54-60 (2011).
2. Stunnenberg, H. G. & Hubner, N. C. Genomics meets proteomics: identifying the culprits in disease. Hum. Genet. 133, 689-700 (2014).
3. Gutierrez-Arcelus, M., Rich, S. S. & Raychaudhuri, S. Autoimmune diseases-connecting risk alleles with molecular traits of the immune system. Nat. Rev. Genet. 17, 160-174 (2016).
4. Melzer, D. et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 4, e1000072 (2008).
5. Lourdusamy, A. et al. Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum. Mol. Genet. 21, 3719-3726 (2012).
6. Johansson, Å. et al. Identification of genetic variants influencing the human plasma proteome. Proc. Natl Acad. Sci. USA 110, 4673-4678 (2013).
7. Kim, S. et al. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS ONE 8, e70269 (2013).
8. Liu, Y. et al. Quantitative variability of 342 plasma proteins in a human twin population. Mol. Syst. Biol. 11, 786 (2015).
9. Enroth, S., Johansson, A., Enroth, S. B. & Gyllensten, U. Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. Nat. Commun. 5, 4684 (2014).
10. Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5, e15004 (2010).
11. Wichmann, H.-E., Gieger, C. & Illig, T. KORA-gen-resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 67, S26-S30 (2005).
12. Mook-Kanamori, D. O. et al. 1, 5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control. J. Clin. Endocrinol. Metab. 99, E479-E483 (2014).
13. Arnold, M., Raffler, J., Pfeufer, A., Suhre, K. & Kastenmüller, G. SNiPA: an interactive, genetic variant-centered annotation browser. Bioinformatics 31, 1334-1336 (2014).
14. Dichgans, M. et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke 45, 24-36 (2014).
15. Qi, L. et al. Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum. Mol. Genet. 19, 1856-1862 (2010).
16. Dentali, F. et al. Non-O blood type is the commonest genetic risk factor for VTE: Results from a meta-analysis of the literature. Semin. Thromb. Hemost. 38, 535-547 (2012).
17. Wolpin, B. M. et al. Pancreatic cancer risk and ABO blood group alleles: results from the Pancreatic Cancer Cohort Consortium. Cancer Res. 70, 1015-1023 (2010).
18. Fry, A. E. et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum. Mol. Genet. 17, 567-576 (2008).
19. Koyama, H. et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 108, 524-529 (2003).
20. Shin, S.-Y. et al. An atlas of genetic influences on human blood metabolites. Nat. Genet. 46, 543-550 (2014).
21. Altmaier, E. et al. Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism. Eur. J. Epidemiol. 29, 325-336 (2014).
22. Chan, B., Yuan, H. T., Ananth Karumanchi, S. & Sukhatme, V. P. Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules. Biochem. Biophys. Res. Commun. 371, 475-479 (2008).
23. Morrow, D., Cullen, J. P., Cahill, P. A. & Redmond, E. M. Cyclic strain regulates the Notch/CBF-1 signaling pathway in endothelial cells: Role in angiogenic activity. Arterioscler. Thromb. Vasc. Biol. 27, 1289-1296 (2007).
24. Zanetti, A. et al. Vascular endothelial growth factor induces Shc association with vascular endothelial cadherin: a potential feedback mechanism to control vascular endothelial growth factor receptor-2 signaling. Arterioscler. Thromb. Vasc. Biol. 22, 617-622 (2002).
25. Nilsson, I. et al. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J. 29, 1377-1388 (2010).
26. Lu, K. V. et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22, 21-35 (2012).
27. Stannard, A. K. et al. Vascular endothelial growth factor synergistically enhances induction of E-selectin by tumor necrosis factor-a. Arterioscler. Thromb. Vasc. Biol. 27, 494-502 (2007).
28. Smith, G. A. et al. Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease. J. Inherit. Metab. Dis. 753-763 (2015).
29. He, M. et al. A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and alpha fetoprotein and their associations with cancer risk. Gut 63, 143-151 (2013).
30. Yue, T. et al. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics 11, 3665-3674 (2011).
31. Narimatsu, H. et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients1. Cancer Res. 58, 512-518 (1998).
32. Vestergaard, E. M. et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin. Chem. 45, 54-61 (1999).
33. Ritchie, G. E. et al. Glycosylation and the complement system. Chem. Rev. 102, 305-319 (2002).
34. Arnold, J. N. et al. Interaction of mannan binding lectin with? 2 macroglobulin via exposed oligomannose glycans: a conserved feature of the thiol ester protein family? J. Biol. Chem. 281, 6955-6963 (2006).
35. Song, G. G. et al. Meta-analysis of functional MBL polymorphisms. Z. Rheumatol. 73, 657-664 (2014).
36. Stahl, E. A. et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat. Genet. 44, 483-489 (2012).
37. Evans, D. M. et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat. Genet. 43, 761-767 (2011).
38. Zervoudi, E. et al. Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses. Proc. Natl Acad. Sci. USA 110, 19890-19895 (2013).
39. Hattori, A. & Tsujimoto, M. Endoplasmic reticulum aminopeptidases: biochemistry, physiology and pathology. J. Biochem. 154, 219-228 (2013).
40. Martin-Esteban, A., Gomez-Molina, P., Sanz-Bravo, A. & De Castro, J. A. L. Combined effects of ankylosing spondylitis-associated erap1 polymorphisms outside the catalytic and peptide-binding sites on the processing of natural HLA-B27 ligands. J. Biol. Chem. 289, 3978-3990 (2014).
41. Reeves, E., Edwards, C. J., Elliott, T. & James, E. Naturally occurring erap1 haplotypes encode functionally distinct alleles with fine substrate specificity. J. Immunol. 191, 35-43 (2013).
42. Hellwage, J. et al. Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett. 462, 345-352 (1999).
43. Frimat, M. et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122, 282-292 (2013).
44. Petersen, A.-K. et al. On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies. BMC Bioinformatics 13, 120 (2012).
45. Bai, B. et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc. Natl Acad. Sci. USA 110, 16562-16567 (2013).
46. Miura, K. et al. Genome-wide association study of HPV-associated cervical cancer in Japanese women. J. Med. Virol. 1158, 1153-1158 (2014).
47. Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621-631 (2015).
48. Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12, 581-594 (2013).
49. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379, 1214-1224 (2012).
50. Suhre, K. & Gieger, C. Genetic variation in metabolic phenotypes: study designs and applications. Nat. Rev. Genet. 13, 759-769 (2012).
51. Shen, Y., Yang, L. & Li, R. What does complement do in Alzheimer's disease? Old molecules with new insights. Transl. Neurodegener. 2, 21 (2013).
52. Foss, E. J. et al. Genetic basis of proteome variation in yeast. Nat. Genet. 39, 1369-1375 (2007).
53. Wu, L. et al. Variation and genetic control of protein abundance in humans. Nature 499, 79-82 (2013).
54. Hause, R. J. et al. Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels. Am. J. Hum. Genet. 95, 194-208 (2014).
55. Garge, N. et al. Identification of quantitative trait loci underlying proteome variation in human lymphoblastoid cells. Mol. Cell. Proteomics 9, 1383-1399 (2010).
56. Claussnitzer, M. et al. Leveraging cross-species transcription factor binding site patterns: From diabetes risk loci to disease mechanisms. Cell 156, 343-358 (2014).
57. Claussnitzer, M. et al. FTO obesity variant circuitry and adipocyte browning in humans. N. Engl. J. Med. 373, 895-907 (2015).
58. Ngo, D. et al. Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease. Circulation 134, 270-285 (2016).
59. Illig, T. et al. A genome-wide perspective of genetic variation in human metabolism. Nat. Genet. 42, 137-141 (2010).
60. Petersen, A.-K. K. et al. Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits. Hum. Mol. Genet. 23, 534-545 (2014).
61. Kraemer, S. et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS ONE 6, e26332 (2011).
62. Hathout, Y. et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc. Natl Acad. Sci. 112, 201507719 (2015).
63. Sattlecker, M. et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement. 10, 724-734 (2014).
64. Kiddle, S. J. et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J. Alzheimers Dis. 38, 515-531 (2014).
65. Menni, C. et al. Circulating proteomic signatures of chronological age. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 70, 809-816 (2015).
66. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
67. McLaren, W. et al. Deriving the consequences of genomic variants with the ensembl API and SNP effect predictor. Bioinformatics 26, 2069-2070 (2010).
68. Hindorff, L. A. et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106, 9362-9367 (2009).
69. Bonder, M. J. et al. Disease variants alter transcription factor levels and methylation of their binding sites. Nat. Gen 49, 131-138 (2017).
70. Raffler, J. et al. Genome-wide association study with targeted and non-targeted NMR metabolomics identifies 15 novel loci of urinary human metabolic individuality. PLoS Genet. 11, e1005487 (2015).
71. Trbojević Akmacić, I. et al. High throughput glycomics: optimization of sample preparation. Biochemistry 80, 934-942 (2015).
72. Lappalainen, T. et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501, 506-511 (2013).